PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. TPS4146-TPS4146 ◽  
Author(s):  
Ghassan K. Abou-Alfa ◽  
Peter R. Galle ◽  
Yee Chao ◽  
Karen T. Brown ◽  
Jeong Heo ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systemic Therapy ◽  
Advanced Hepatocellular Carcinoma ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Study ◽  
Label Study ◽  
Oncolytic Immunotherapy ◽  
Prior Systemic Therapy

scholarly journals Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population

Cancer ◽  
2008 ◽  
Vol 115 (2) ◽  
pp. 428-436 ◽  
Author(s):  
Thomas Yau ◽  
Pierre Chan ◽  
Kelvin K. Ng ◽  
Sin Ho Chok ◽  
Tan To Cheung ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis B ◽  
Single Agent ◽  
Asian Population ◽  
Advanced Hepatocellular Carcinoma ◽  
Phase 2 ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

scholarly journals HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma

2016 ◽  
Vol 11 (2) ◽  
pp. 199-208 ◽  
Author(s):  
Shi-Ming Lin ◽  
Sheng-Nan Lu ◽  
Ping-Tsung Chen ◽  
Long-Bin Jeng ◽  
Shinn-Cherng Chen ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Advanced Hepatocellular Carcinoma ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Phase Iv

scholarly journals A Phase Ib, Open‐Label Study of Dalantercept, an Activin Receptor‐Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma

2018 ◽  
Vol 24 (2) ◽  
pp. 161 ◽  
Author(s):  
Ghassan K. Abou‐Alfa ◽  
Rebecca A. Miksad ◽  
Mohamedtaki A. Tejani ◽  
Stephen Williamson ◽  
Martin E. Gutierrez ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Advanced Hepatocellular Carcinoma ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Activin Receptor ◽  
Phase Ib ◽  
Receptor Like Kinase

Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

2012 ◽  
Vol 18 (7) ◽  
pp. 2090-2098 ◽  
Author(s):  
Richard S. Finn ◽  
Yoon-Koo Kang ◽  
Mary Mulcahy ◽  
Blase N. Polite ◽  
Ho Yeong Lim ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Phase Ii ◽  
Advanced Hepatocellular Carcinoma ◽  
Second Line ◽  
Open Label ◽  
Second Line Therapy ◽  
Open Label Study ◽  
Label Study ◽  
Line Therapy

scholarly journals Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

2011 ◽  
Vol 17 (7) ◽  
pp. 1973-1983 ◽  
Author(s):  
Joong-Won Park ◽  
Richard S. Finn ◽  
Jun Suk Kim ◽  
Mark Karwal ◽  
Ruby K. Li ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Phase Ii ◽  
Advanced Hepatocellular Carcinoma ◽  
First Line ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
First Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document